Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome

被引:2
|
作者
Liu, Chia-Chu [1 ,2 ,3 ,4 ]
Huang, Shu-Pin [1 ,2 ]
Lee, Yung-Chin [1 ,2 ,5 ]
Lee, Cheng-Hsueh [1 ]
Huang, Tsung-Yi [1 ]
Geng, Jiun-Hung [2 ,5 ]
Chang, Che-Wei [1 ,3 ]
Lin, Chung-Yu [1 ]
Juan, Yung-Shun [1 ,2 ]
Wu, Wen-Jeng [1 ,2 ]
Hsieh, Tusty-Jiuan [4 ,6 ]
机构
[1] Kaohsiung Med Univ, Dept Urol, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol, Kaohsiung, Taiwan
[3] Pingtung Hosp, Dept Urol, Minist Hlth & Welf, Pingtung, Taiwan
[4] Kaohsiung Med Univ, Res Ctr Precis Environm Med, Kaohsiung, Taiwan
[5] Kaohsiung Municipal Siaogang Hosp, Dept Urol, Kaohsiung, Taiwan
[6] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
metabolic dysfunction-associated fatty liver disease; testosterone deficiency; aging men; metabolic syndrome; insulin resistance; ANDROGEN DEFICIENCY; RISK; PREVALENCE;
D O I
10.3389/fendo.2023.1252774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a valuable marker for identifying individuals at increased risk of metabolic dysfunction, liver-related complications, and cardiovascular disease. However, the association between MAFLD and testosterone deficiency (TD) in aging men remains poorly understood. This study aimed to investigate the association between MAFLD and the risk of TD in aging Taiwanese men, with a specific focus on those without metabolic syndrome (MetS).Methods: A free health screening program was conducted for Taiwanese men aged over 40 years in Kaohsiung, Taiwan. Participants underwent physical examinations, completed questionnaires regarding demographics, medical history, and clinical symptoms of TD, and provided 20-mL whole blood samples for biochemical, adipocytokine, and hormonal evaluations. Fatty liver index was used to evaluate the risk of fatty liver. Diagnostic criteria for MAFLD included fatty liver along with overweight/obesity, type 2 diabetes, or evidence of metabolic dysregulation.Results: A total of 631 men (mean age: 54.4 +/- 8.4 years) were enrolled. The prevalence rates of TD and MetS were significantly higher in men with MAFLD compared to those without (both p < 0.001). Additionally, the presence of MAFLD showed a significant correlation with adipocytokines associated with insulin resistance, such as adiponectin, leptin, and retinol-binding protein-4 (RBP-4) levels (all p < 0.001). Among men without MetS, those with MAFLD had a 3.89- and 4.74-fold higher risk of total testosterone < 300 ng/dL and TD, respectively, after adjusting for potential covariates.Conclusion: MAFLD is associated with an elevated risk of TD in aging Taiwanese men, particularly in the absence of MetS. This finding suggests that MAFLD could serve as an early predictor of TD, facilitating the identification of high-risk individuals and enabling timely interventions. Further research is needed to validate these findings and explore the underlying mechanisms linking MAFLD, TD, and MetS in diverse populations.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
    Barchetta, Ilaria
    Cimini, Flavia Agata
    Cavallo, Maria Gisella
    NUTRIENTS, 2020, 12 (11) : 1 - 14
  • [32] An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
    Zhang, Le
    El-Shabrawi, Mortada
    Baur, Louise A.
    Byrne, Christopher D.
    Targher, Giovanni
    Kehar, Mohit
    Porta, Gilda
    Lee, Way Seah
    Lefere, Sander
    Turan, Serap
    Alisi, Anna
    Weiss, Ram
    Faienza, Maria Felicia
    Ashraf, Ambika
    Sundaram, Shikha S.
    Srivastava, Anshu
    De Bruyne, Ruth
    Kang, Yunkoo
    Bacopoulou, Flora
    Zhou, Yong-Hai
    Darma, Andy
    Lupsor-Platon, Monica
    Hamaguchi, Masahide
    Misra, Anoop
    Mendez-Sanchez, Nahum
    Ng, Nicholas Beng Hui
    Marcus, Claude
    Staiano, Amanda E.
    Waheed, Nadia
    Alqahtani, Saleh A.
    Giannini, Cosimo
    Ocama, Ponsiano
    Nguyen, Mindie H.
    Arias-Loste, Maria Teresa
    Ahmed, Mohamed Rabea
    Sebastiani, Giada
    Poovorawan, Yong
    Al Mahtab, Mamun
    Pericas, Juan M.
    da Silveira, Themis Reverbel
    Hegyi, Peter
    Azaz, Amer
    Isa, Hasan M.
    Lertudomphonwanit, Chatmanee
    Farrag, Mona Issa
    Nugud, Ahmed Abd Alwahab
    Du, Hong-Wei
    Qi, Ke-Min
    Mouane, Nezha
    Cheng, Xin-Ran
    MED, 2024, 5 (07): : 797 - +
  • [33] Metabolic dysfunction-associated fatty liver disease and osteoporosis: the mechanisms and roles of adiposity
    Tao, Jie
    Li, Hong
    Wang, Honggang
    Tan, Juan
    Yang, Xiaozhong
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (12) : 2087 - 2098
  • [34] Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment
    Yu, Qiang
    He, Ruixin
    Jiang, Haowen
    Wu, Ji
    Xi, Zhifeng
    He, Kang
    Liu, Yongbo
    Zhou, Tao
    Feng, Mingxuan
    Wan, Ping
    Yan, Hexin
    Xia, Qiang
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (06) : 1034 - 1041
  • [35] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [36] Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
    Zhou, Xiao-Dong
    Cai, Jingjing
    Targher, Giovanni
    Byrne, Christopher D.
    Shapiro, Michael D.
    Sung, Ki-Chul
    Somers, Virend K.
    Chahal, C. Anwar A.
    George, Jacob
    Chen, Li-Li
    Zhou, Yong
    Zheng, Ming-Hua
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [37] Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
    van Kleef, Laurens A.
    Ayada, Ibrahim
    Alferink, Louise J. M.
    Pan, Qiuwei
    Knegt, Robert J.
    HEPATOLOGY, 2022, 75 (02) : 419 - 429
  • [38] Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay
    Arvanitakis, Konstantinos
    Chatzikalil, Elena
    Kalopitas, Georgios
    Patoulias, Dimitrios
    Popovic, Djordje S.
    Metallidis, Symeon
    Kotsa, Kalliopi
    Germanidis, Georgios
    Koufakis, Theocharis
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [39] The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
    Paklar, Natasa
    Mijic, Maja
    Filipec-Kanizaj, Tajana
    BIOMEDICINES, 2023, 11 (11)
  • [40] The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population
    Song, Xiao-Hui
    Liu, Bo
    Lei, Fang
    Liu, Ye-Mao
    Zhang, Xingyuan
    Chen, Ze
    Zhang, Peng
    Zhang, Xiao-Jing
    She, Zhi-Gang
    Cai, Jingjing
    Wang, Jin-Hua
    Li, Hongliang
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 373 - 384